Recently listed biotechnology company; specific pipeline and disease focus not confidently known.
Recently listed biotechnology company; specific pipeline and disease focus not confidently known.
Moat: none
Size Braveheart Bio (BRVE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.67B, the 1894th largest of 3,085 United States companies the cockpit tracks. Shares closed at $18.53 on 18 Nov 2026.
Capital Return on invested capital runs 41.3 points below its cost of capital (6.6% WACC).
Short interest Short interest is 5.7% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | |
|---|---|---|
| Revenue | n/a | $0 |
| Revenue growth | — | — |
| Gross profit | n/a | $0 |
| EBITDA | n/a | -$65.4M |
| Net income | n/a | -$66.1M |
| Free cash flow | n/a | -$2.01M |
| Capital expenditure | n/a | $0 |
| Total debt | $515,000 | $0 |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BRVE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.6% | -3.2% | 6th lowest of 21 |
| Distance from 52-week high | -42.1% | -34.3% | 6th lowest of 21 |
| ROIC minus cost of capital | -41.3 pp | -1.0 pp | 3rd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 8.9× | 18.4% | +10.8% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 2.2× | -14.9% | +13.5% |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 3.6× | 31.4% | +29.4% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 2.3× | -3.5% | +6.8% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 6.3× | 24.3% | +15.7% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 16.7× | 11.3% | -11.0% |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 2.6× | 3.7% | +9.9% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | 68.8× | n/a | n/a |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | 12.2× | 33.0% | +0.9% |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 9.7× | 35.3% | +9.2% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | 5.6× | 42.4% | +23.0% |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 7.2× | n/a | n/a |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 5.1× | 20.5% | +19.0% |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 9.8× | 31.1% | -15.1% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 5.2× | 12.8% | -14.0% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 1.2× | -6.6% | -5.6% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 2.0× | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 4.5× | 6.0% | -4.3% |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 2.5× | n/a | n/a |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | 8.3× | n/a | n/a |